23 min listen
Taking a Portfolio Approach to Immuno-Oncology
FromThe Bio Report
ratings:
Length:
33 minutes
Released:
Aug 5, 2021
Format:
Podcast episode
Description
While the class of immunotherapies known as checkpoint inhibitors has brought a promising new approach to treating cancer, the development of resistance to these therapies limits the number of patients they benefit. Portage Biotech is building a set of platform technologies and a pipeline of immuno-oncology therapeutic candidates to address this problem. We spoke to Ian Walters, CEO of Portage about the problem of resistance, the company’s pipeline of candidates, and its portfolio-based business model.
Released:
Aug 5, 2021
Format:
Podcast episode
Titles in the series (100)
The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report